Please login to order a test.
DCP is intended for use as an aid in the risk assessment of patients with chronic liver disease for progression to hepatocellular carcinoma in conjunction with other laboratory findings, imaging studies, and clinical assessment.1
Results for this test should not be used as absolute evidence of presence or absence of malignant disease without confirmation of the diagnosis by another medically established diagnostic product or procedure. Values obtained with different assay methods or kits cannot be used interchangeably.
Liquid-phase binding assay (LiBaSys)
0.5 mL (Note: This volume does not allow for repeat testing.)
Separate serum from cells and transfer to a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Causes for Rejection
Nonserum specimen received; nonfrozen specimen received
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|140002||Hepatocellular Carcinoma Risk||130576||Hepatocellular Carcinoma||N/A|
|140002||Hepatocellular Carcinoma Risk||141302||AFP-L3%, Serum||%||42332-7|
|140002||Hepatocellular Carcinoma Risk||141303||AFP, Serum||ng/mL||1834-1|
|140002||Hepatocellular Carcinoma Risk||141326||DCP||ng/mL||34444-0|